What does this research mean for the field?

DARS1 promotes aggressiveness in hepatocellular carcinoma (HCC) by reshaping the proteome and modulating MYC activity through non-canonical SAGA signaling. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aims to investigate the role of DARS1 in hepatocellular carcinoma aggressiveness and its potential as a biomarker.

March 8, 2026

Aspartyl-tRNA synthetase 1 (DARS1) reshapes hepatocellular carcinoma proteome and promotes aggressiveness through non-canonical SAGA–MYC signalling modulation

Key Points

The study aims to investigate the role of DARS1 in hepatocellular carcinoma aggressiveness and its potential as a biomarker.
Analyzed DARS1 expression in hepatocellular carcinoma samples
Examined DARS1's impact on the proteome
Investigated non-canonical interactions with the SAGA complex and MYC
DARS1 is overexpressed in hepatocellular carcinoma tissues and detectable in plasma
Alterations in the proteome linked to DARS1 activity increase cancer aggressiveness
Non-canonical interactions with the SAGA complex modulate MYC signaling

Abstract

DARS1 is frequently overexpressed in HCC and detectable in plasma, supporting its potential as liquid biopsy biomarker. Functionally, DARS1 represents a novel vulnerability of HCC, acting through both proteome reshaping and non-canonical nuclear interactions with the SAGA complex that modulate MYC activity.

Aspartyl-tRNA synthetase 1 (DARS1) reshapes hepatocellular carcinoma proteome and promotes aggressiveness through non-canonical SAGA–MYC signalling modulation

Key Points

Abstract

Cite This Study